Seeking to position Indiana as a global leader in agritechnology and life sciences, Gov. Mike Braun unveiled a lofty goal in a public announcement Tuesday morning.
Indiana’s largest life sciences companies and research universities are working to make the state an international leader in chemistry innovation — and they’re ready to launch the first step in a plan called Catalyze Indiana.
Eli Lilly and Co. has launched a platform that offers employers coverage options for obesity care through a partnership with 18 digital health programs.
Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers after an agreement that will see Novo Nordisk’s branded weight loss medicines sold through the Hims platform.
Tim Coleman has held positions within information technology at Lilly in research and development, sales and marketing, manufacturing, and human resources.
Creating opportunities for internships is an essential component of preparing Indiana students for the world of work as well as increasing the chances that we retain these individuals in our state post-graduation.
The Catalyst Scholars Fund is supported by a $69.4 million grant from Lilly Endowment Inc. to the CICP Foundation Inc. and matching commitments from participating universities.
Elanco Animal Health Inc. stock hit a 52-week high this week after the company posted double-digit revenue growth in the fourth quarter, driven by sales of some of its newest products.
While major drugmakers tussle for market supremacy, they are also taking on compound pharmacies that have not stopped selling obesity drugs despite the end of the shortage of such drugs.
The largely agricultural area has been in the spotlight for several years since state economic development officials began assembling thousands of acres of land for the district.
Once fully operational, the Lebanon campus will employ about 300 people, according to Meta, which said it expects the first buildings will be online by the end of 2027.
Attorney General Todd Rokita announced the settlement Monday, just over a year after filing an antitrust lawsuit against Pfizer Inc., Viatris Inc. and several other companies that distribute injectable epinephrine devices.
The makers of blockbuster GLP-1 drugs, Novo and Indianapolis-based Eli Lilly and Co., have long complained the U.S. Food and Drug Administration hasn’t done enough to stop the proliferation of cheap, compounded weight-loss drugs.
Orna is developing a treatment known as CAR-T cell therapy, a form of immunotherapy that trains a person’s own cells to recognize and destroy diseases.
